Brief: Dimerix Says FDA Ind Approval For Phase 3 Study Of Dmx-200 In FSGS
09/05/2022 09:31
May 9 (Reuters) - Dimerix:
* FDA IND APPROVAL FOR PHASE 3 STUDY OF DMX-200 IN FSGS
Source text for Eikon: ID:nASXc41Ccp
Further company coverage: DXB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dimerix
See all newsAustralia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix To Conduct Review Of Action3 Statistical Assumptions